Work

Multinational, multicenter, retrospective cohort study assessing treatment patterns and outcomes in solid organ transplant recipients considered refractory, resistant, or intolerant to anti-CMV therapies

Year: 2026
Type: article
Study design: Observational Study
Abstract: Introduction Real-world evidence on cytomegalovirus (CMV) infection after solid organ transplant (SOT) is limited, particularly with refractory, resistance, and/or intolerance to anti-CMV agents (RRI). Methods This retrospective chart review study across 15 transplant centers in Canada, Israel, and Europe included adult SOT recipients with RRI CMV infection. Results Overall, patients ( N = 109) experienced 169 CMV episodes, with a median (Q1–Q3) time from SOT to the first CMV episode of 119 days (46–231) and from SOT to RRI diagnosis of 187 (100–296) days. CMV clearance during the first RRI CMV episode was achieved by 83 patients (76.1%) (median time to clearance: 48 days from the start of the index episode, 32 days from RRI diagnosis). Recurrent CMV episodes occurred in 30.3% of patients ( n = 33; median time to recurrence from the end of the index episode, 42 days). In total, 70 patients (64.2%) experienced myelosuppression and 16 (14.7%) experienced nephrotoxicity. Overall, 26 patients (23.9%) experienced organ rejection and 6.4% ( n = 7) graft loss after RRI diagnosis. Overall, 28 patients (25.7%) died following SOT. Conclusion Post-SOT RRI CMV infection may lead to high treatment burden and negatively affect outcomes. There is a need for anti-CMV therapies that can achieve CMV clearance without treatment-limiting toxicities.
Language: English
Subfield: Epidemiology
Field: Medicine
Open Access status: gold
Estimated APC paid: $2,353
OpenAlex ID: W7236669074
FWCI:
Cites: 30
Cited by:
Related to: 10
Parts: 2